Equities

Vericel Corp

Vericel Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)46.57
  • Today's Change-1.46 / -3.04%
  • Shares traded1.06m
  • 1 Year change+43.20%
  • Beta1.6852
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments110120103
Total Receivables, Net584737
Total Inventory131613
Prepaid expenses------
Other current assets, total254.804.25
Total current assets206187158
Property, plant & equipment, net1155759
Goodwill, net------
Intangibles, net6.887.50--
Long term investments252026
Note receivable - long term------
Other long term assets0.771.300.32
Total assets354273244
LIABILITIES
Accounts payable22179.02
Accrued expenses232017
Notes payable/short-term debt000
Current portion long-term debt/capital leases00.040.04
Other current liabilities, total------
Total current liabilities463726
Total long term debt0.1000.04
Total debt0.100.040.09
Deferred income tax------
Minority interest------
Other liabilities, total824347
Total liabilities1288173
SHAREHOLDERS EQUITY
Common stock629593554
Additional paid-in capital------
Retained earnings (accumulated deficit)(403)(400)(383)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.1)(0.98)(0.15)
Total equity226192170
Total liabilities & shareholders' equity354273244
Total common shares outstanding484747
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.